Noven Financial Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Noven Financial Group’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,171	Closed	-$23K	–	42
2016 Q3	$23K	Buy	1,171 +976	+501%	+$138K	0.01%	41
2016 Q2	$23K	Hold	195	–	–	0.02%	38
2016 Q1	$22K	Hold	195	–	–	0.02%	41
2015 Q4	$37K	Buy	195 +71	+57%	+$13.3K	0.03%	39
2015 Q3	$21K	Buy	+124	New	+$44.7K	0.02%	36

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Noven Financial Group's VIRX Position: Q4 2016 in Review

Noven Financial Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2016, closing a stake of 1,171 shares — an estimated $23K sold.

Noven Financial Group first reported a position in VIRX in Q3 2015 and held it in 5 quarters. The position peaked at $37K in Q4 2015. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

Noven Financial Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Noven Financial Group sold 1,171 Viracta Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $23K.
Noven Financial Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2015 and held it in 5 quarters.
Noven Financial Group's Viracta Therapeutics, Inc. Common Stock position peaked at $37K in Q4 2015.
45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Noven Financial Group's 13F filing for Q4 2016, filed 13 Feb 2017.